The "99% pure” on the label may be the most persuasive phrase in the research-peptide market.

It sounds definitive. Scientific. Almost impossible to argue with.

But a purity percentage is not a universal grade for everything inside a vial. It is the output of a particular analytical method, performed on a particular sample, under particular testing conditions.

We spoke to Olympus Peptide Labs. Here's what we learned

A report showing 99% purity does not automatically establish:

• That the material is the peptide named on the label
• That the vial contains the labeled number of milligrams
• That every relevant impurity was detected
• That the material is sterile
• That endotoxins or microorganisms are absent
• That the product remained stable after testing
• That the report belongs to the batch being sold
• That the material is suitable for a particular experiment

This distinction is not merely semantic. International analytical guidance treats identity, purity and impurities, and assay or content as separate analytical questions. One result cannot automatically substitute for the others.

A Certificate of Analysis, or COA, can be valuable evidence. But only when the buyer understands what each part of it actually proves.

Start With the Most Basic Question: Does This COA Belong to Your Batch?

Before evaluating the purity percentage, confirm that the report applies to the exact material being offered.

A credible batch-specific COA should ordinarily identify:

• Product name
• Peptide sequence or unambiguous chemical identity
• Salt or counterion form, where relevant
• Lot or batch number
• Sample or report number
• Date received
• Date tested
• Laboratory name
• Analytical methods performed
• Results and acceptance criteria
• Authorized review or signature

The lot number on the report should match the lot number on the product.

A generic report labeled only “BPC-157,” “CJC-1295,” or “TB-500” is weaker than a report tied to a specific production batch. A QR code is useful only when it resolves to the documentation for the actual lot, not a permanent marketing page displaying the same report for every order.

Chemical naming also matters. A free base, acetate salt, DAC-modified peptide, and non-DAC peptide are not interchangeable simply because a familiar name appears somewhere on the report.

That problem is not hypothetical. In a 2024 evaluation involving CJC-1295-related substances, FDA reviewers found inconsistencies among the nominated substance, chemical name, molecular formula, molecular weight, salt form, and the form discussed in supporting references. The document illustrates why a recognizable product name alone is not enough to establish exactly what was tested.

First rule

No batch match, no reliable conclusion.

No batch match, no reliable conclusion.

What HPLC Purity Actually Measures

High-performance liquid chromatography, or HPLC, separates compounds according to how they interact with a chromatographic column and the mobile phase passing through it.

As components exit the column, a detector records a signal. The result is a chromatogram containing peaks.

Under a simplified area-normalization calculation:

```

Purity percentage =

Area of the designated primary peak

÷

Total integrated peak area

×

100

```

If the primary peak represents 99% of the integrated signal, the report may state approximately 99% chromatographic purity.

That can be useful. It suggests that, under that particular method, the tested sample was dominated by one detected chromatographic component.

But that result answers a narrow question.

A 99% HPLC result does not necessarily mean:

• 99% of the total vial weight is active peptide
• The vial contains 99% of its labeled milligram amount
• The largest peak has been conclusively identified
• Every impurity was detected
• All impurities were resolved into separate peaks
• The material is sterile or free from endotoxin
• The sample will remain 99% pure throughout storage

HPLC is a separation method. The quality of the conclusion depends on the specificity of the method, the detector, reference standards, integration settings, sample preparation, and whether relevant substances were successfully separated.

Two compounds can sometimes elute too closely to be cleanly distinguished. This is called co-elution. An impurity hidden beneath the primary peak may not appear as a separate peak in a basic area calculation.

FDA has specifically recommended higher-resolution liquid chromatography coupled with high-resolution tandem mass spectrometry when necessary to identify peptide impurities, evaluate peak purity, and investigate substances that may co-elute.

What to inspect on the chromatogram

Do not stop at the percentage printed in the summary box. Look for:

• The complete chromatogram
• Retention time of the principal peak
• Integration markers
• Visible secondary peaks
• Solvent-front or injection artifacts
• Detector wavelength
• Column type
• Mobile phases
• Gradient conditions
• Run time
• Reference-standard comparison
• System-suitability results
• The method used to calculate area percentage

A chromatogram with no method information is difficult to evaluate. A cropped image showing one large peak and no baseline is weaker than a complete analytical record.

HPLC Purity and Peptide Identity Are Not the Same Thing

A sample can produce a dominant chromatographic peak without that peak being the compound expected by the buyer.

This is why identity testing matters.

HPLC asks:

How much of the detected chromatographic signal belongs to the selected peak?

Identity testing asks:

Is the material represented by that peak actually the peptide named on the label?

Is the material represented by that peak actually the peptide named on the label?

Retention time can contribute to identification when compared against an appropriate reference standard, but retention time alone is rarely the strongest possible identity evidence.

That is where mass spectrometry becomes useful.

What Mass Spectrometry Adds

Mass spectrometry, or MS, measures ions according to their mass-to-charge ratio.

For a synthetic peptide, the laboratory can compare the observed molecular mass with the theoretical mass expected from the proposed sequence and chemical form.

A typical report may show:

• Expected molecular mass
• Observed molecular mass
• Mass-to-charge peaks
• Multiple charge states
• Mass accuracy or error
• The assigned molecular ion
• An MS or MS/MS spectrum

Agreement between the theoretical and observed mass provides meaningful evidence that the material is consistent with the expected peptide.

Mass spectrometry is widely used to characterize synthetic-peptide identity, while tandem mass spectrometry can provide additional sequence information through controlled fragmentation.

But mass spectrometry is not automatically a substitute for chromatography.

A mass spectrum can support identity without telling the buyer how much of the total sample consists of the desired material. Conversely, HPLC can report a high relative purity without conclusively establishing the identity of the primary peak.

The stronger combination

```

HPLC or UHPLC

+

Mass spectrometry

+

Batch-specific documentation

```

The methods answer complementary questions:

• Chromatography: What components are present, and in what relative proportions?
• Mass spectrometry: Is the observed mass consistent with the proposed peptide?
• Assay or content testing: How much target material is actually present?
• Additional testing: Are relevant chemical or microbiological attributes controlled?

For higher-level characterization, regulators and pharmacopeial scientists use combinations of chromatography, mass spectrometry, nuclear magnetic resonance, amino-acid analysis, water testing, and other orthogonal techniques rather than expecting one result to establish every quality attribute.

Why 99% Purity Does Not Prove the Vial Contains the Labeled Milligrams

Imagine that a vial is labeled as containing 10 milligrams.

An HPLC result of 99% does not necessarily prove that 9.9 milligrams of target peptide are present.

The total mass of a lyophilized material can include more than the target peptide:

• Water
• Counterions such as acetate or trifluoroacetate
• Residual solvents
• Salts
• Excipients or bulking agents
• Process-related residues
• Peptide-related impurities

Chromatographic purity describes the relative composition of the material detected by the method. It is not automatically an absolute measurement of the target peptide per vial.

A quantitative assay, calibrated against an appropriate standard, is needed when the research question concerns actual peptide content.

Depending on the product and analytical objective, this may involve:

• Quantitative HPLC
• Amino-acid analysis
• Nitrogen analysis
• UV quantitation where technically appropriate
• Gravimetric or fill-weight controls
• Water determination
• Counterion analysis
• A combination of methods

USP work on synthetic-peptide reference standards treats water, identity, content, and chromatographic purity as distinct elements of characterization. That is a useful model for understanding why “99% pure” and “10 milligrams present” are not identical claims.

The practical question

Do not ask only:

What is the HPLC purity?

What is the HPLC purity?

Also ask:

What method supports the labeled peptide content?

What method supports the labeled peptide content?

The Missing Question: What Is in the Remaining 1%?

Suppose the purity result is legitimate and the sample is 99% target peptide by the stated method.

What makes up the other 1%?

Potential synthetic-peptide impurities can include:

• Truncated sequences
• Deletion sequences
• Incomplete coupling products
• Modified side chains
• Oxidized products
• Deamidated products
• Isomeric impurities
• Aggregates
• Residual reagents
• Residual solvents
• Protecting-group remnants
• Degradation products

The percentage alone does not identify those substances.

That matters because one unknown impurity is not automatically equivalent to another. The analytical importance of an impurity depends on its identity, concentration, chemical behavior, and the requirements of the intended laboratory model.

FDA’s CJC-1295 evaluation provides an unusually clear example. A submitted COA reported 99% peptide purity, but reviewers noted that it did not adequately characterize the nature of individual impurities and did not include certain testing related to aggregates, bioburden, or endotoxin. FDA also explained that peptide synthesis can produce truncations, side-reaction products, isomers, process residues, and aggregates that may require sophisticated methods to identify and quantify.

The lesson is not that a 99% result is worthless.

The lesson is that 99% is the beginning of the analysis, not the end of it.

Purity Testing Does Not Establish Sterility

HPLC and mass spectrometry are chemical analytical tools.

They do not, by themselves, establish the absence of:

• Viable bacteria
• Fungi
• Bacterial endotoxins
• Particulate contamination
• Microbial contamination introduced after testing

These require separate and appropriate test procedures.

For laboratory work involving sensitive cell systems, microbiological conditions may be highly relevant. A buyer should ask whether the intended experiment requires:

• Sterility testing
• Microbial-limits testing
• Bacterial-endotoxin testing
• Bioburden testing
• Particulate analysis
• Container-closure evaluation

A report that lists only HPLC and MS should not be interpreted as evidence for microbiological attributes that were never tested. FDA quality documentation similarly treats identity, purity, assay, water, microbial burden, endotoxin, and other characteristics as separate controls selected according to the material and intended use.

A COA Is a Snapshot, Not a Lifetime Warranty

A COA describes the sample at the time it was tested.

It does not automatically prove that the material remained unchanged after:

• Long-term storage
• Exposure to heat
• Repeated temperature cycling
• Moisture exposure
• Improper transportation
• Damaged packaging
• Reconstitution
• Extended storage after preparation

A serious quality system distinguishes between:

• Release testing
• Stability testing
• Retest dates
• Storage requirements
• Shipping conditions
• In-use stability

The testing date therefore matters.

A technically sound report from an unrelated or much older batch does not establish the present condition of a newly produced lot.

Seven Questions to Ask Before Trusting a Peptide COA

1. Does the report match the exact lot?

Match the batch number on the report to the material being purchased and delivered.

2. Is the chemical identity unambiguous?

Confirm the peptide name, sequence, modification, salt form, and other chemically meaningful distinctions.

3. Is the complete HPLC chromatogram available?

Look beyond the summary percentage. Review the trace, integration, method, and secondary peaks.

4. Is identity supported by mass spectrometry or another appropriate method?

Compare the expected and observed molecular mass. Stronger documentation may include tandem-MS or orthogonal identity testing.

5. Is there evidence for actual peptide content?

A purity percentage does not automatically validate the labeled milligrams.

6. Were the attributes relevant to the experiment actually tested?

Chemical purity, content, sterility, endotoxin, water, residual solvents, aggregation, and stability are separate questions.

7. Can the testing laboratory and report be verified?

The report should identify the laboratory and provide enough information to trace the test. Laboratory independence, accreditation, method competence, and sample custody may all affect the weight given to the result.

Common COA Red Flags

Be cautious when:

• The same report appears on every batch
• The lot number is absent
• The product name is chemically ambiguous
• The testing date predates the stated production batch
• Only the final percentage is shown
• The chromatogram is heavily cropped
• No mass spectrum or identity test is provided
• The observed mass is missing
• The report has no identifiable laboratory
• The QR code opens a generic product page
• The report provides no method information
• A 10-milligram claim is supported only by HPLC area percentage
• Every product conveniently reports the same extreme purity
• The supplier refuses to provide current batch documentation

No single red flag automatically proves that a product is defective. But several together should reduce confidence.

The Correct Way to Read “99% Pure”

A careful interpretation would sound like this:

The tested sample produced a principal chromatographic peak representing approximately 99% of the integrated signal under the stated HPLC method. Separate evidence is still required to establish peptide identity, absolute content, relevant impurity characterization, microbiological attributes, stability, and correspondence to the delivered batch.

The tested sample produced a principal chromatographic peak representing approximately 99% of the integrated signal under the stated HPLC method. Separate evidence is still required to establish peptide identity, absolute content, relevant impurity characterization, microbiological attributes, stability, and correspondence to the delivered batch.

That statement is less exciting than a large 99% PURE badge.

That statement is less exciting than a large 99% PURE badge.

It is also far more scientifically honest.

The Bottom Line

A COA is not a magic certificate and it is not proof that a product is safe, legal, sterile, correctly filled, or suitable for every research application.

It is an analytical document.

Its value depends on:

• Whether it belongs to the right batch
• Whether the product identity is unambiguous
• Which methods were used
• Whether those methods were appropriate
• Whether the raw results are visible
• Whether the conclusions stay within what the tests can actually prove

The best research buyers do not ask whether a supplier “has COAs.”

They ask whether the documentation answers the specific analytical questions their work requires.

Research-Use Notice

Olympus Peptide Labs supplies materials for laboratory research and analytical investigation only. Products are not intended for human or veterinary consumption and are not intended to diagnose, treat, cure, or prevent disease.

Before purchasing any research material, review the documentation available for the exact product and lot. Where a required test is not shown, request clarification rather than assuming that the attribute was evaluated.